Read the latest news about research and scientific resultats on Alzheimer's disease at the Barcelonaβeta Brain Research Center (BBRC).
More than 900 people without cognitive alterations from the Alfa Study, which has the support of the "la Caixa" Foundation, have participated in the research.
The study, which used data from almost 400 participants of the ALFA+ Study, determines that the biomarkers p-tau231 and p-tau217 measured in the blood are suitable for indicating brain changes related to the amyloid protein in people without cognitive symptoms.
Research helps to better understand the relationship between biomarkers of Alzheimer’s disease and the pathophysiological mechanisms that are altered in their early stages.
The thesis develved into urrent knowledge of the disease during its preclinical stage and provides new evidence for its early detection.
Researchers at the Pasqual Maragall Foundation's research center, the Barcelonaβeta Brain Research Center (BBRC), with the support of the “la Caixa” Foundation, have detected that the glial fibrillar acid protein (GFAP) is a very accurate biomarker for diagnosing in blood the early stages of Alzheimer’s disease.
The organization under the European Commission will finance part of the project
Interview with Gemma Salvadó, researcher of the Neuroimaging Group, after obtaining her PhD
Researchers at the Barcelonaβeta Brain Research Center (BBRC) have identified that people with amyloid pathology and subjective cognitive impairment have an increase in light neurofilaments (NfL) in the cerebrospinal fluid and a lower volume in the hippocampus.
A study led by the BBRC, with the support of the “la Caixa” Foundation, suggests that people at increased risk of developing Alzheimer's experience weight loss that would precede cognitive impairment.